Details
Stereochemistry | RACEMIC |
Molecular Formula | C10H15NO2.ClH |
Molecular Weight | 217.693 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN[C@@H](C)[C@H](O)C1=CC=C(O)C=C1
InChI
InChIKey=ICBZSKCTKKUQSY-YUWZRIFDSA-N
InChI=1S/C10H15NO2.ClH/c1-7(11-2)10(13)8-3-5-9(12)6-4-8;/h3-7,10-13H,1-2H3;1H/t7-,10-;/m0./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/27062112Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18500382
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27062112
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18500382
Oxilofrine is a sympathomimetic used to treat hypotensive states, with cardiac stimulatory effects similar to those of ephedrine. It has never been approved for use in the USA as a prescription drug or as a dietary supplement. Oxilofrine has been found (1) to act predominantly as a beta1 agonist increasing the speed and force of heart muscle contraction (inotropic effects), specifically, increasing left ventricular ejection fraction and stroke volume; (2) to increase blood pressure; (3) to have variable effects on heart rate; and (4) to potentially increase oxygen uptake by the lungs.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18500382
Curator's Comment: Oxilofrine is a sympathomimetic used to treat hypotensive states, with actions similar to those of ephedrine.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27062112
Curator's Comment: Original source: G. Liljestrand, P. Linde. Die Wirkung von Oxy-ephedrinen auf Gaswechsel und Kreislauf beim Menschen. Arch. Inter. Pharmacodyn. Ther. 1933, 45, 318.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27062112 |
|||
Target ID: GO:0014061 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7191269 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | OXILOFRINE Approved UseOxilofrine has been used in a variety of medications to treat low blood pressure, to manage asthma exacerbations, to suppress coughing, and to enhance cardiac function during anesthesia. |
|||
Palliative | OXILOFRINE Approved UseOxilofrine has been used in a variety of medications to treat low blood pressure, to manage asthma exacerbations, to suppress coughing, and to enhance cardiac function during anesthesia. |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27062112 |
Primary | OXILOFRINE Approved UseOxilofrine has been used in a variety of medications to treat low blood pressure, to manage asthma exacerbations, to suppress coughing, and to enhance cardiac function during anesthesia. |
||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27062112 |
Secondary | OXILOFRINE Approved UseOxilofrine has been used in a variety of medications to treat low blood pressure, to manage asthma exacerbations, to suppress coughing, and to enhance cardiac function during anesthesia. |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27062112
The usual adult dose is 32 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7191269
Experiments in vitro have shown oxilofrine to release noradrenaline from rat cardiac ventricular sections. This effect sets in at a concentration of 10^-5 mol/l and reaches the 30% level at 5*10^-5 mol/l. The inhibition of noradrenaline storage is still more pronounced. At 5*10^-5 mol/l the inhibition is 60%.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000085488
Created by
admin on Fri Dec 15 15:11:23 GMT 2023 , Edited by admin on Fri Dec 15 15:11:23 GMT 2023
|
PRIMARY | |||
|
DBSALT001920
Created by
admin on Fri Dec 15 15:11:23 GMT 2023 , Edited by admin on Fri Dec 15 15:11:23 GMT 2023
|
PRIMARY | |||
|
12625680
Created by
admin on Fri Dec 15 15:11:23 GMT 2023 , Edited by admin on Fri Dec 15 15:11:23 GMT 2023
|
PRIMARY | |||
|
3O9694M5EO
Created by
admin on Fri Dec 15 15:11:23 GMT 2023 , Edited by admin on Fri Dec 15 15:11:23 GMT 2023
|
PRIMARY | |||
|
942-51-8
Created by
admin on Fri Dec 15 15:11:23 GMT 2023 , Edited by admin on Fri Dec 15 15:11:23 GMT 2023
|
PRIMARY | |||
|
SUB03572MIG
Created by
admin on Fri Dec 15 15:11:23 GMT 2023 , Edited by admin on Fri Dec 15 15:11:23 GMT 2023
|
PRIMARY | |||
|
DTXSID90273983
Created by
admin on Fri Dec 15 15:11:23 GMT 2023 , Edited by admin on Fri Dec 15 15:11:23 GMT 2023
|
PRIMARY | |||
|
213-392-5
Created by
admin on Fri Dec 15 15:11:23 GMT 2023 , Edited by admin on Fri Dec 15 15:11:23 GMT 2023
|
PRIMARY | |||
|
236554
Created by
admin on Fri Dec 15 15:11:23 GMT 2023 , Edited by admin on Fri Dec 15 15:11:23 GMT 2023
|
PRIMARY | RxNorm |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD